Opus Genetics – the next BEST thing!
The latest research news from Retina UK.
Search
Search results
Belite Bio – Phase 2/3 Trial for Adolescents with Stargardt disease
The latest research news piece from Retina UK.
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
Retina-on-a-chip: the tiny technology offering big hope for inherited sight loss
Researchers in the Netherlands are developing a “retina-on-a-chip” that mimics the key layers of the human retina, offering a powerful new way to study inherited retinal diseases (IRDs) and test potential treatments using human cells.
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).
Data protection complaints
Data Protection complaints and data rights request form.
We are sorry that you are unhappy with how our organisation is using or processing your personal data.
Notice of the forthcoming Retina UK AGM – July 2026
Formal notice of the forthcoming Annual General Meeting in July 2026.
Clinical Trial Opportunity for Adults with Stargardt Disease
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
Seeing the light: Scientists use photoswitch drugs to restore vision in animal study
A consortium of researchers based at the Institute for Bioengineering of Catalonia (IBEC) have demonstrated that specially designed light-activated drugs can restore useful visual function in blind animals by making surviving retinal nerve cells respond to light.